Corcept Therapeutics Quarterly Income Statement
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corcept Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Corcept Therapeutics generated $256.1 million in revenue, up 31.7% from the same quarter a year earlier. Net income was $43.0 million (+22.3% year over year), for a net margin of 16.8% versus a median of 12.0% in the prior 5 quarters. Gross margin was 98.4% (up from 98.2%) and operating margin 16.1%.
Diluted earnings per share came in at $0.36, up from $0.29.
Summary generated from market data by MetaCap's automated system. Methodology
Corcept Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 256.15M | 164.90M | 202.13M | 207.64M | 194.43M | 157.21M | 181.89M | 182.55M | 163.80M | 146.81M | 135.41M | 123.60M |
| Revenue growth (YoY) | +31.74% | +4.89% | +11.12% | +13.75% | +18.70% | +7.09% | +34.33% | +47.69% | +39.15% | +38.95% | +31.39% | +21.50% |
| Cost of Revenue | 4.06M | 2.88M | 2.54M | 4.60M | 3.43M | 2.40M | 2.96M | 2.87M | 2.52M | 2.54M | 1.88M | 1.65M |
| Gross Profit | 252.09M | 162.02M | 199.58M | 203.04M | 191.00M | 154.81M | 178.93M | 179.68M | 161.27M | 144.27M | 133.53M | 121.96M |
| Operating Expenses | 210.79M | 211.62M | 195.09M | 192.82M | 164.32M | 151.40M | 153.67M | 133.08M | 125.68M | 114.77M | 101.86M | 90.78M |
| Research & Development | 53.89M | 66.27M | 64.86M | 68.85M | 60.47M | 60.73M | 70.30M | 59.34M | 58.74M | 58.51M | 54.71M | 45.52M |
| Selling, General & Admin | 156.90M | 145.36M | 130.24M | 123.98M | 103.85M | 90.66M | 83.37M | 73.75M | 66.94M | 56.27M | 47.15M | 45.26M |
| Operating Income | 41.30M | -49.60M | 4.49M | 10.22M | 26.68M | 3.42M | 25.26M | 46.60M | 35.59M | 29.50M | 31.67M | 31.18M |
| Other Income (Expense) | 4.63M | 4.89M | 5.42M | 5.02M | 5.02M | 6.20M | 6.70M | 6.34M | 6.00M | 5.49M | 5.14M | 5.21M |
| Pretax Income | 45.93M | -44.72M | 9.91M | 15.24M | 31.69M | 9.62M | 31.96M | 52.94M | 41.60M | 34.99M | 36.81M | 36.38M |
| Income Tax | 2.94M | -12.95M | -14.38M | -4.42M | -3.46M | -10.93M | 1.21M | 5.73M | 6.11M | 7.23M | 5.45M | 5.01M |
| Net Income | 42.99M | -31.76M | 24.29M | 19.67M | 35.15M | 20.55M | 30.75M | 47.21M | 35.49M | 27.76M | 31.36M | 31.38M |
| Net Income growth (YoY) | +22.30% | -254.58% | -21.00% | -58.34% | -0.96% | -25.99% | -1.94% | +50.47% | +28.92% | +74.83% | +88.87% | -9.33% |
| EPS (Basic) | 0.40 | -0.30 | 0.24 | 0.19 | 0.33 | 0.19 | 0.29 | 0.45 | 0.34 | 0.27 | 0.29 | 0.31 |
| EPS (Diluted) | 0.36 | -0.30 | 0.20 | 0.16 | 0.29 | 0.17 | 0.25 | 0.41 | 0.32 | 0.25 | 0.27 | 0.28 |
| Shares Outstanding (Basic) | 105.38M | 104.44M | — | 103.55M | 104.11M | 104.11M | — | 103.37M | 103.12M | 102.79M | — | 102.01M |
| Shares Outstanding (Diluted) | 118.39M | 104.44M | — | 119.44M | 120.48M | 119.82M | — | 113.72M | 111.24M | 109.92M | — | 111.10M |
| EBITDA | 42.16M | -49.00M | 4.78M | 10.15M | 27.14M | 3.88M | 25.54M | 46.92M | 35.67M | 29.62M | 31.88M | 31.41M |
| Gross Margin | 98.41% | 98.25% | 98.74% | 97.79% | 98.23% | 98.47% | 98.37% | 98.43% | 98.46% | 98.27% | 98.61% | 98.67% |
| Operating Margin | 16.12% | -30.08% | 2.22% | 4.92% | 13.72% | 2.17% | 13.89% | 25.53% | 21.73% | 20.09% | 23.39% | 25.22% |
| Net Margin | 16.78% | -19.26% | 12.02% | 9.47% | 18.08% | 13.07% | 16.90% | 25.86% | 21.67% | 18.91% | 23.16% | 25.39% |
This table shows 12 quarterly periods of Corcept Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CORT's reporting calendar. What is a income statement?